Deciphering downstream receptor signaling

Marta Filizola,Jonathan A Javitch

DOI: https://doi.org/10.1126/science.adm8393

IF: 56.9

2023-12-22

Science

Abstract:Advancing drug discovery requires increasingly integrative structural biology approaches.

What problem does this paper attempt to address?

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Tao Wang,Mianbin Wu,Ri-Hao Zhang,Zheng-Jie Chen,Chen Hua,Jianping Lin,Li-Rong Yang

DOI: https://doi.org/10.2174/1568026615666150825142002

2016-01-01

Current Topics in Medicinal Chemistry

Abstract:Compared with the increasing and widespread bacterial resistance to clinical medicines and the urgent need for cures of intractable diseases, there is a dramatic decline in the numbers of drugs reaching the market or clinical trials. Accordingly, it has become imperative to discover more rational and efficient strategies to design and develop novel drugs. Structure-based drug design/discovery (SBDD) is one of the computer-aided methods, by which novel drugs are designed or discovered based on the knowledge of 3D structures of the relevant specific targets. During the past few decades, the great potentials and success of SBDD have been seen in the field of drug discovery. In this review, we present an overview of the key mechanisms of SBDD, the frequently used computer programs in SBDD and the reported successful cases. Finally, several typical design processes of lead components from SBDD are also highlighted in detail, such as the discovery of inhibitors of G protein-coupled receptors (GPCRs), antibacterial drugs, and anti-cancer drugs.
Deciphering molecular determinants of GPCR-G protein receptor interactions by complementary integrative structural biology methods

Jerome Castel,Thomas Botzanowski,Ieva Brooks,Alexandre Frechard,Gilbert Bey,Marine Schroeter,Elise Del Nero,Francois Debaene,Fabrice Ciesielski,Denis Zeyer,Sarah Cianferani,Renaud Morales

DOI: https://doi.org/10.1101/2024.10.21.619395

2024-10-24

Abstract:Many physiological processes are dependent on G protein-coupled receptors (GPCRs), the biggest family of human membrane proteins and a significant class of therapeutic targets. Once activated by external stimuli, GPCRs use G proteins and arrestins as transducers to generate second messengers and trigger downstream signaling, leading to diverse signaling profiles. The G protein-coupled bile acid receptor 1 (GPBAR1, also known as Takeda G protein-coupled receptor 5, TGR5) is a class A bile acid membrane receptor that regulates energy homeostasis and glucose and lipid metabolism. GPBAR1/G protein interactions are implicated in the prevention of diabetes and the reduction of inflammatory responses, making GPBAR1 a potential therapeutic target for metabolic disorders. Here, we present an integrated structural biology approach combining hydrogen/deuterium exchange mass spectrometry (HDX-MS) and cryo-electron microscopy (cryo-EM) to identify the molecular determinants of GPBAR1 conformational dynamics upon G protein binding. Thanks to extensive optimization of both HDX-MS and cryo-EM workflows, we achieved over 99% sequence coverage along with a 2.5-A resolution structure, both of which are state-of-the-art and solely obtained for complete GPCR complexes. Altogether, our results provide information on the under-investigated GPBAR1 binding mode to its cognate G protein, pinpointing the synergic and powerful combination of higher (cryo-EM) and lower (HDX-MS) resolution structural biology techniques to dissect GPCR/G protein binding characteristics.

Biophysics
Integrated Molecular Modeling and Machine Learning for Drug Design

Song Xia,Eric Chen,Yingkai Zhang

DOI: https://doi.org/10.1021/acs.jctc.3c00814

2023-11-14

Abstract:Modern therapeutic development often involves several stages that are interconnected, and multiple iterations are usually required to bring a new drug to the market. Computational approaches have increasingly become an indispensable part of helping reduce the time and cost of the research and development of new drugs. In this Perspective, we summarize our recent efforts on integrating molecular modeling and machine learning to develop computational tools for modulator design, including a pocket-guided rational design approach based on AlphaSpace to target protein-protein interactions, delta machine learning scoring functions for protein-ligand docking as well as virtual screening, and state-of-the-art deep learning models to predict calculated and experimental molecular properties based on molecular mechanics optimized geometries. Meanwhile, we discuss remaining challenges and promising directions for further development and use a retrospective example of FDA approved kinase inhibitor Erlotinib to demonstrate the use of these newly developed computational tools.
Computational drug development for membrane protein targets

Haijian Li,Xiaolin Sun,Wenqiang Cui,Marc Xu,Junlin Dong,Babatunde Edukpe Ekundayo,Dongchun Ni,Zhili Rao,Liwei Guo,Henning Stahlberg,Shuguang Yuan,Horst Vogel

DOI: https://doi.org/10.1038/s41587-023-01987-2

IF: 46.9

2024-02-01

Nature Biotechnology

Abstract:The application of computational biology in drug development for membrane protein targets has experienced a boost from recent developments in deep learning-driven structure prediction, increased speed and resolution of structure elucidation, machine learning structure-based design and the evaluation of big data. Recent protein structure predictions based on machine learning tools have delivered surprisingly reliable results for water-soluble and membrane proteins but have limitations for development of drugs that target membrane proteins. Structural transitions of membrane proteins have a central role during transmembrane signaling and are often influenced by therapeutic compounds. Resolving the structural and functional basis of dynamic transmembrane signaling networks, especially within the native membrane or cellular environment, remains a central challenge for drug development. Tackling this challenge will require an interplay between experimental and computational tools, such as super-resolution optical microscopy for quantification of the molecular interactions of cellular signaling networks and their modulation by potential drugs, cryo-electron microscopy for determination of the structural transitions of proteins in native cell membranes and entire cells, and computational tools for data analysis and prediction of the structure and function of cellular signaling networks, as well as generation of promising drug candidates.

biotechnology & applied microbiology
Exploring Diverse Signaling Mechanisms of G Protein-Coupled Receptors through Structural Biology

Ryoji Suno

DOI: https://doi.org/10.1093/jb/mvae018

2024-02-21

The Journal of Biochemistry

Abstract:Abstract Recent advancements in structural biology have facilitated the elucidation of complexes involving G protein-coupled receptors (GPCRs) and their associated signal transducers, including G proteins and arrestins. A comprehensive analysis of these structures provides profound insights into the dynamics of signaling mechanisms. These structural revelations can potentially guide the development of drugs to minimize side effects through targeted and selective signaling. Understanding the binding modes of different signal-selective ligands is imperative for future drug research and development. Here, we conduct a comparative examination of the structural details of various GPCR-signal transducer complexes and delve into the molecular basis of the currently proposed signal selectivity.

biochemistry & molecular biology
Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform

Liping Yang,Timothy P. Sheets,Yang Feng,Guojun Yu,Pradip Bajgain,Kuo-Sheng Hsu,Daeho So,Steven Seaman,Jaewon Lee,Ling Lin,Christine N. Evans,Mary R. Guest,Raj Chari,Brad St. Croix

DOI: https://doi.org/10.1126/sciadv.adj2445

IF: 13.6

2024-02-16

Science Advances

Abstract:The majority of clinically approved drugs target proteins that are secreted or cell surface bound. However, further advances in this area have been hindered by the challenging nature of receptor deorphanization, as there are still many secreted and cell-bound proteins with unknown binding partners. Here, we developed an advanced screening platform that combines CRISPR-CAS9 guide–mediated gene activation (CRISPRa) and high-avidity bead-based selection. The CRISPRa platform incorporates serial enrichment and flow cytometry–based monitoring, resulting in substantially improved screening sensitivity for well-known yet weak interactions of the checkpoint inhibitor family. Our approach has successfully revealed that siglec-4 exerts regulatory control over T cell activation through a low affinity trans-interaction with the costimulatory receptor 4-1BB. Our highly efficient screening platform holds great promise for identifying extracellular interactions of uncharacterized receptor-ligand partners, which is essential to develop next-generation therapeutics, including additional immune checkpoint inhibitors.

multidisciplinary sciences
Decipher: A computational pipeline to extract context-specific mechanistic insights from single-cell profiles

Edgar Basto,Bilal Wajid,James Read,Jesse Armitage,Jason Waithman,Michael Small,Anthony Bosco

DOI: https://doi.org/10.1101/2024.05.01.591681

2024-05-03

Abstract:The advent of single-cell profiling technologies has revolutionized our understanding of the cellular and molecular states that underpin disease states and response to therapies. However, current computational tools cannot recover both known and novel mechanistic insights at distinct layers of biological regulation in an unbiased manner. Here, we present , a novel computational pipeline that builds integrated cell signalling networks from single-cell profiles in a context-specific, data-driven manner and identifies the key cellular and molecular events that drive disease. We benchmarked against existing tools and found it could recover known, experimentally determined cytokine signalling pathways with high accuracy, whilst maintaining the flexibility to detect novel pathways and context-specific effects. Notably, reports a manageable set of interactions that can be aggregated into global cell-to-cell signalling maps that are interpretable. In addition, we utilised to unveil the cellular and molecular mechanisms driving a novel population of inflammatory monocytes enriched with interferon stimulated genes that is markedly increased in frequency following secondary immunization with the Pfizer-BioNTech COVID-19 mRNA vaccine. Taken together, our findings demonstrate that can decode signalling pathways and report on ligand-receptor mediated transcription factor – target gene networks that underlie processes in homeostasis and disease, as well as cellular responses to therapies. We present as an invaluable new tool for the discovery of novel therapeutic targets and the development of new medicines.

Bioinformatics
Exploring structure-function relationships in engineered receptor performance using computational structure prediction

William K Corcoran,Amparo Cosio,Hailey Ilyse Edelstein,Joshua N Leonard

DOI: https://doi.org/10.1101/2024.11.07.622438

2024-11-07

Abstract:Engineered receptors play increasingly important roles in transformative cell-based therapies. However, the structural mechanisms that drive differences in performance across receptor designs are often poorly understood. Recent advances in protein structural prediction tools have enabled the modeling of virtually any user-defined protein, but how these tools might build understanding of engineered receptors has yet to be fully explored. In this study, we employed structural modeling tools to perform post hoc analyses to investigate whether predicted structural features might explain observed functional variation. We selected a recently reported library of receptors derived from natural cytokine receptors as a case study, generated structural models, and from these predictions quantified a set of structural features that plausibly impact receptor performance. Encouragingly, for a subset of receptors, structural features explained considerable variation in performance, and trends were largely conserved across structurally diverse receptor sets. This work indicates potential for structure prediction-guided synthetic receptor engineering.

Synthetic Biology
The role of experimental and computational structural approaches in 7TM drug discovery

Sid Topiol,Michael Sabio

DOI: https://doi.org/10.1517/17460441.2015.1072166

2015-07-27

Expert Opinion on Drug Discovery

Abstract:INTRODUCTION: Starting with the published X-ray structures of ligand-mediated 7TM proteins in 2007, experimental approaches, led by X-ray structure determinations, and computational approaches, led by docking and molecular dynamics, have converged to elaborate our understanding of this field and demonstrate their effectiveness in drug discovery.AREAS COVERED: The authors review the structural information that has emerged for ligand-mediated 7TM proteins, including the class A, B, C, and F receptors, focusing on the 7TM domains for the multi-domain proteins. The authors describe the key regions associated with ligand binding as well as features responsible for function such as activation versus inhibition and biased signaling. Furthermore, the authors summarize the effectiveness of computational studies to help clarify the structure-function information and their use for drug discovery.EXPERT OPINION: There is now a significant amount of structural information covering a range of 7TM protein classes (A, B, C, and F) and activation states. For these and closely related proteins, structure-based drug discovery has proven to be a powerful tool. More structural information is needed with respect to dimerization, 7TM proteins with β-arrestin to help in understanding the control of biased signaling, and full-protein structure determinations for non-class A proteins to help in understanding and controlling their functioning. Finally, the use of the existing structural information to target new sites on these proteins needs further exploration.

pharmacology & pharmacy
Structure, function and drug discovery of GPCR signaling

Lin Cheng,Fan Xia,Ziyan Li,Chenglong Shen,Zhiqian Yang,Hanlin Hou,Suyue Sun,Yuying Feng,Xihao Yong,Xiaowen Tian,Hongxi Qin,Wei Yan,Zhenhua Shao

DOI: https://doi.org/10.1186/s43556-023-00156-w

2023-12-04

Abstract:G protein-coupled receptors (GPCRs) are versatile and vital proteins involved in a wide array of physiological processes and responses, such as sensory perception (e.g., vision, taste, and smell), immune response, hormone regulation, and neurotransmission. Their diverse and essential roles in the body make them a significant focus for pharmaceutical research and drug development. Currently, approximately 35% of marketed drugs directly target GPCRs, underscoring their prominence as therapeutic targets. Recent advances in structural biology have substantially deepened our understanding of GPCR activation mechanisms and interactions with G-protein and arrestin signaling pathways. This review offers an in-depth exploration of both traditional and recent methods in GPCR structure analysis. It presents structure-based insights into ligand recognition and receptor activation mechanisms and delves deeper into the mechanisms of canonical and noncanonical signaling pathways downstream of GPCRs. Furthermore, it highlights recent advancements in GPCR-related drug discovery and development. Particular emphasis is placed on GPCR selective drugs, allosteric and biased signaling, polyphamarcology, and antibody drugs. Our goal is to provide researchers with a thorough and updated understanding of GPCR structure determination, signaling pathway investigation, and drug development. This foundation aims to propel forward-thinking therapeutic approaches that target GPCRs, drawing upon the latest insights into GPCR ligand selectivity, activation, and biased signaling mechanisms.
Recent Advances in Structure, Function, and Pharmacology of Class A Lipid GPCRs: Opportunities and Challenges for Drug Discovery

R. N. V. Krishna Deepak,Ravi Kumar Verma,Yossa Dwi Hartono,Wen Shan Yew,Hao Fan

DOI: https://doi.org/10.3390/ph15010012

IF: 4.6

2021-12-22

Pharmaceuticals

Abstract:Great progress has been made over the past decade in understanding the structural, functional, and pharmacological diversity of lipid GPCRs. From the first determination of the crystal structure of bovine rhodopsin in 2000, much progress has been made in the field of GPCR structural biology. The extraordinary progress in structural biology and pharmacology of GPCRs, coupled with rapid advances in computational approaches to study receptor dynamics and receptor-ligand interactions, has broadened our comprehension of the structural and functional facets of the receptor family members and has helped usher in a modern age of structure-based drug design and development. First, we provide a primer on lipid mediators and lipid GPCRs and their role in physiology and diseases as well as their value as drug targets. Second, we summarize the current advancements in the understanding of structural features of lipid GPCRs, such as the structural variation of their extracellular domains, diversity of their orthosteric and allosteric ligand binding sites, and molecular mechanisms of ligand binding. Third, we close by collating the emerging paradigms and opportunities in targeting lipid GPCRs, including a brief discussion on current strategies, challenges, and the future outlook.

pharmacology & pharmacy,chemistry, medicinal
Accelerating drug discovery and repurposing by combining transcriptional signature connectivity with docking

Alexander W Thorman,James Reigle,Somchai Chutipongtanate,Juechen Yang,Behrouz Shamsaei,Marcin Pilarczyk,Mehdi Fazel-Najafabadi,Rafal Adamczak,Michal Kouril,Surbhi Bhatnagar,Sarah Hummel,Wen Niu,Ardythe L Morrow,Maria F Czyzyk-Krzeska,Robert McCullumsmith,William Seibel,Nicolas Nassar,Yi Zheng,David A Hildeman,Mario Medvedovic,Andrew B Herr,Jarek Meller

DOI: https://doi.org/10.1126/sciadv.adj3010

2024-08-30

Abstract:We present an in silico approach for drug discovery, dubbed connectivity enhanced structure activity relationship (ceSAR). Building on the landmark LINCS library of transcriptional signatures of drug-like molecules and gene knockdowns, ceSAR combines cheminformatic techniques with signature concordance analysis to connect small molecules and their targets and further assess their biophysical compatibility using molecular docking. Candidate compounds are first ranked in a target structure-independent manner, using chemical similarity to LINCS analogs that exhibit transcriptomic concordance with a target gene knockdown. Top candidates are subsequently rescored using docking simulations and machine learning-based consensus of the two approaches. Using extensive benchmarking, we show that ceSAR greatly reduces false-positive rates, while cutting run times by multiple orders of magnitude and further democratizing drug discovery pipelines. We further demonstrate the utility of ceSAR by identifying and experimentally validating inhibitors of BCL2A1, an important antiapoptotic target in melanoma and preterm birth-associated inflammation.
Structure-based drug design: From nucleic acid to membrane protein targets

Magdalena M. Dailey,Chayanendu Hait,Patrick A. Holt,Jon M. Maguire,Jason B. Meier,M. Clarke Miller,Luigi Petraccone,John O. Trent

DOI: https://doi.org/10.1016/j.yexmp.2009.01.011

IF: 4.401

2009-06-01

Experimental and Molecular Pathology

Abstract:The in silico methods for drug discovery are becoming increasingly powerful and useful. That, in combination with increasing computer processor power, in our case using a novel distributed computing grid, has enabled us to greatly enhance our virtual screening efforts. Herein we review some of these efforts using both receptor and ligand-based virtual screening, with the goal of finding new anti-cancer agents. In particular, nucleic acids are a neglected set of targets, especially the different morphologies of duplex, triplex, and quadruplex DNA, many of which have increasing biological relevance. We also review examples of molecular modeling to understand receptors and using virtual screening against G-protein coupled receptor membrane proteins.

pathology
Next generation of network medicine: interdisciplinary signaling approaches

Tamas Korcsmaros,Maria Victoria Schneider,Giulio Superti-Furga

DOI: https://doi.org/10.1039/c6ib00215c

2017-01-20

Integrative Biology

Abstract:In the last decade, network approaches have transformed our understanding of biological systems. Network analyses and visualizations have allowed us to identify essential molecules and modules in biological systems, and improved our understanding of how changes in cellular processes can lead to complex diseases, such as cancer, infectious and neurodegenerative diseases. "Network medicine" involves unbiased large-scale network-based analyses of diverse data describing interactions between genes, diseases, phenotypes, drug targets, drug transport, drug side-effects, disease trajectories and more. In terms of drug discovery, network medicine exploits our understanding of the network connectivity and signaling system dynamics to help identify optimal, often novel, drug targets. Contrary to initial expectations, however, network approaches have not yet delivered a revolution in molecular medicine. In this review, we propose that a key reason for the limited impact, so far, of network medicine is a lack of quantitative multi-disciplinary studies involving scientists from different backgrounds. To support this argument, we present existing approaches from structural biology, 'omics' technologies (e.g., genomics, proteomics, lipidomics) and computational modeling that point towards how multi-disciplinary efforts allow for important new insights. We also highlight some breakthrough studies as examples of the potential of these approaches, and suggest ways to make greater use of the power of interdisciplinarity. This review reflects discussions held at an interdisciplinary signaling workshop which facilitated knowledge exchange from experts from several different fields, including in silico modelers, computational biologists, biochemists, geneticists, molecular and cell biologists as well as cancer biologists and pharmacologists.

cell biology
Decoding the Molecular Dance: In Silico Exploration of Cannabinoid Interactions with Key Protein Targets for Therapeutic Insights

Westley Cruces,Maite Docampo-Palcios,Giovanni Ramirez,Tesfay Tesfatsion,Monica Pittiglio,Kyle Ray

DOI: https://doi.org/10.26434/chemrxiv-2023-7jxvh-v2

2024-01-10

Abstract:As hemp-based cannabinoids are continuously gaining popularity, synthesis and extraction methods for these compounds are ever-changing. Within the cannabinoid market, hydrogenated derivatives are also gaining popularity at an accelerated rate, with the need for in-depth analysis of these compounds pertinent to increasing the knowledge of cannabis chemistry. Our lab used Schrödinger to dock natural and synthetic cannabinoids in various CB1 and CB2 receptors, PPAR-γ, PAK1, and GPR119 complex including several enzymes, to evaluate the interacting residues within the known binding pockets, comprising the computation of binding energies, predicting ADME characteristics, and evaluating P450 sites of metabolism. The purpose of identifying active residues, sites of metabolism, and ADME characteristics for 40 various cannabinoids is to provide guidance in computer-aided drug design and rationalization in designing and synthesis of analogs.

Chemistry
Molecular interaction networks and drug development: Novel approach to drug target identification and drug repositioning

Joseph Loscalzo

DOI: https://doi.org/10.1096/fj.202201683R

2022-12-07

The FASEB Journal

Abstract:Conventional drug discovery requires identifying a protein target believed to be important for disease mechanism and screening compounds for those that beneficially alter the target's function. While this approach has been an effective one for decades, recent data suggest that its continued success is limited largely owing to the highly prevalent irreducibility of biologically complex systems that govern disease phenotype to a single primary disease driver. Network medicine, a new discipline that applies network science and systems biology to the analysis of complex biological systems and disease, offers a novel approach to overcoming these limitations of conventional drug discovery. Using the comprehensive protein–protein interaction network (interactome) as the template through which subnetworks that govern specific diseases are identified, potential disease drivers are unveiled and the effect of novel or repurposed drugs, used alone or in combination, is studied. This approach to drug discovery offers new and exciting unbiased possibilities for advancing our knowledge of disease mechanisms and precision therapeutics.

cell biology,biochemistry & molecular biology,biology
Elucidating structural and molecular mechanisms of β-arrestin-biased agonism at GPCRs via MS-based proteomics

Kunhong Xiao,Jinpeng Sun

DOI: https://doi.org/10.1016/j.cellsig.2017.09.013

IF: 4.85

2018-01-01

Cellular Signalling

Abstract:The discovery of β-arrestin-dependent GPCR signaling has led to an exciting new field in GPCR pharmacology: to develop “biased agonists” that can selectively target a specific downstream signaling pathway that elicits beneficial therapeutic effects without activating other pathways that elicit negative side effects. This new trend in GPCR drug discovery requires us to understand the structural and molecular mechanisms of β-arrestin-biased agonism, which largely remain unclear. We have used cutting-edge mass spectrometry (MS)-based proteomics, combined with systems, chemical and structural biology to study protein function, macromolecular interaction, protein expression and posttranslational modifications in the β-arrestin-dependent GPCR signaling. These high-throughput proteomic studies have provided a systems view of β-arrestin-biased agonism from several perspectives: distinct receptor phosphorylation barcode, multiple receptor conformations, distinct β-arrestin conformations, and ligand-specific signaling. The information obtained from these studies offers new insights into the molecular basis of GPCR regulation by β-arrestin and provides a potential platform for developing novel therapeutic interventions through GPCRs.
Computational elucidation of allosteric communication in proteins for allosteric drug design

Duan Ni,Yaqin Liu,Ren Kong,Zhengtian Yu,Shaoyong Lu,Jian Zhang

DOI: https://doi.org/10.1016/j.drudis.2022.03.012

IF: 8.369

2022-03-01

Drug Discovery Today

Abstract:Allosteric modulators target topologically distal allosteric sites in order to modulate orthosteric sites, providing enhanced specificity and physiochemical properties. Harnessing allostery for drug discovery is an emerging paradigm in modern pharmaceutics. Allosteric regulation substantially depends on the propagation of allosteric signaling. Delineating allosteric signaling pathways is therefore one of the leading prerequisites for allosteric drug discovery. Allosteric signal transduction is...

pharmacology & pharmacy
Elucidation and refinement of synthetic receptor mechanisms

Hailey I Edelstein,Patrick S Donahue,Joseph J Muldoon,Anthony K Kang,Taylor B Dolberg,Lauren M Battaglia,Everett R Allchin,Mihe Hong,Joshua N Leonard

DOI: https://doi.org/10.1093/synbio/ysaa017

IF: 3.244

2020-01-01

Synthetic Biology

Abstract:Abstract Synthetic receptors are powerful tools for engineering mammalian cell-based devices. These biosensors enable cell-based therapies to perform complex tasks such as regulating therapeutic gene expression in response to sensing physiological cues. Although multiple synthetic receptor systems now exist, many aspects of receptor performance are poorly understood. In general, it would be useful to understand how receptor design choices influence performance characteristics. In this study, we examined the modular extracellular sensor architecture (MESA) and systematically evaluated previously unexamined design choices, yielding substantially improved receptors. A key finding that might extend to other receptor systems is that the choice of transmembrane domain (TMD) is important for generating high-performing receptors. To provide mechanistic insights, we adopted and employed a Förster resonance energy transfer-based assay to elucidate how TMDs affect receptor complex formation and connected these observations to functional performance. To build further insight into these phenomena, we developed a library of new MESA receptors that sense an expanded set of ligands. Based upon these explorations, we conclude that TMDs affect signaling primarily by modulating intracellular domain geometry. Finally, to guide the design of future receptors, we propose general principles for linking design choices to biophysical mechanisms and performance characteristics.
Decoding anaphylatoxins: unveiling the molecular mechanisms of complement receptor activation and signaling

Francisco J Fernández,M Cristina Vega,Francisco J. Fernández,M. Cristina Vega

DOI: https://doi.org/10.1016/j.tibs.2024.01.001

2024-01-01

Trends in Biochemical Sciences

Abstract:Recent advances in cryo-electron microscopy (Cryo-EM) have revolutionized our understanding of the complement C5a/C3a receptors that are crucial in inflammation. A recent report by Yadav et al. has elucidated the activation, ligand binding, selectivity, and signaling bias of these receptors, thereby enhancing structure-guided drug discovery. This paves the way for more effective anti-inflammatory therapies that target these receptors with unprecedented precision.

biochemistry & molecular biology

Deciphering downstream receptor signaling

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Deciphering molecular determinants of GPCR-G protein receptor interactions by complementary integrative structural biology methods

Integrated Molecular Modeling and Machine Learning for Drug Design

Computational drug development for membrane protein targets

Exploring Diverse Signaling Mechanisms of G Protein-Coupled Receptors through Structural Biology

Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform

Decipher: A computational pipeline to extract context-specific mechanistic insights from single-cell profiles

Exploring structure-function relationships in engineered receptor performance using computational structure prediction

The role of experimental and computational structural approaches in 7TM drug discovery

Structure, function and drug discovery of GPCR signaling

Recent Advances in Structure, Function, and Pharmacology of Class A Lipid GPCRs: Opportunities and Challenges for Drug Discovery

Accelerating drug discovery and repurposing by combining transcriptional signature connectivity with docking

Structure-based drug design: From nucleic acid to membrane protein targets

Next generation of network medicine: interdisciplinary signaling approaches

Decoding the Molecular Dance: In Silico Exploration of Cannabinoid Interactions with Key Protein Targets for Therapeutic Insights

Molecular interaction networks and drug development: Novel approach to drug target identification and drug repositioning

Elucidating structural and molecular mechanisms of β-arrestin-biased agonism at GPCRs via MS-based proteomics

Computational elucidation of allosteric communication in proteins for allosteric drug design

Elucidation and refinement of synthetic receptor mechanisms

Decoding anaphylatoxins: unveiling the molecular mechanisms of complement receptor activation and signaling